Microsomal epoxide hydrolase deletion enhances tyrosine hydroxylase phosphorylation in mice after MPTP treatment

Journal of Neuroscience Research

Volumn 86, Issue 12, 2008, Pages 2792-2801

  Liu, Mei ^a   Hunter, Randy ^a   Nguyen, Xuan V ^a   Kim, Hyoung Chun ^b   Bing, Guoying ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

^b Kangwon National University   (South Korea)

Author keywords

Epoxide hydrolase; Parkinson's disease; Substantia nigra

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE; EPOXIDE HYDROLASE; MICROSOME ENZYME; NEUROTOXIN; SERINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CELL LOSS; CONTROLLED STUDY; DOPAMINE METABOLISM; DOPAMINERGIC NERVE CELL; ENVIRONMENTAL STRESS; ENZYME ACTIVITY; ENZYME DEFICIENCY; ENZYME PHOSPHORYLATION; ENZYME REGULATION; GENE DELETION; IMMUNOBLOTTING; IMMUNOFLUORESCENCE; IMMUNOREACTIVITY; KNOCKOUT MOUSE; MICROSOME; MOUSE; NEUROMODULATION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN LOCALIZATION; SUBSTANTIA NIGRA; TURNOVER TIME; WILD TYPE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; ASTROCYTES; EPOXIDE HYDROLASES; GENE DELETION; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICROSOMES; PHOSPHORYLATION; TYROSINE 3-MONOOXYGENASE;

EID: 57049090465     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21725     Document Type: Article

References (42)

1. Ahmadi A,Fredrikson M,Jerregard H,Akerback A,Fall PA,Rannug A,Axelson O,Soderkvist P. 2000. GSTM1 and mEPHX polymorphisms in Parkinson's disease and age of onset. Biochem Biophys Res Commun 269: 676-680.
2. Appel SH. 1981. A unifying hypothesis for the cause of amyotrophic lateral sclerosis, parkinsonism, and Alzheimer disease. Ann Neurol 10: 499-505.
3. Arai N,Misugi K,Goshima Y,Misu Y. 1990. Evaluation of a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated C57 black mouse model for parkinsonism. Brain Res 515: 57-63.
4. Betarbet R,Sherer TB,MacKenzie G,Garcia-Osuna M,Panov AV,Greenamyre JT. 2000. Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci 3: 1301-1306.
5. Brown RG,Marsden CD. 1984. How common is dementia in Parkinson's disease? Lancet 2(8414): 1262-1265.
6. Burns RS,Chiueh CC,Markey SP,Ebert MH,Jacobowitz DM,Kopin IJ. 1983. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci U S A 80: 4546-4550.
7. Cass WA,Harned ME,Peters LE,Nath A,Maragos WF 2003. HIV-1 protein Tat potentiation of methamphetamine-induced decreases in evoked overflow of dopamine in the striatum of the rat. Brain Res 984: 133-142.
8. Chen Y,Vartiainen NE,Ying W,Chan PH,Koistinaho J,Swanson RA. 2001. Astrocytes protect neurons from nitric oxide toxicity by a glutathione-dependent mechanism. J Neurochem 77: 1601-1610.
9. Fretland AJ,Omiecinski CJ. 2000. Epoxide hydrolases: biochemistry and molecular biology. Chemicobiol Interactions 129: 41-59.
10. Gaedigk A,Spielberg SP,Grant DM. 1994. Characterization of the microsomal epoxide hydrolase gene in patients with anticonvulsant adverse drug reactions. Pharmacogenetics 4: 142-153.
11. Gerlach M,Riederer P. 1996. Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man. JNeural Transm 103: 987-1041.
12. Gerlach M,Aoutsilieri E,Riederer P. 1998. N-methyl-(R)-salsolinol and its relevance to Parkinson's disease. Lancet 351(9106): 850-851.
13. GiassonBI,Forman MS,Higuchi M,Golbe LI,Graves CL,Kotzbauer PT,Trojanowski JQ,Lee VM. 2003. Initiation and synergistic fibrillization of tau and alpha-synuclein. Science 300(5619): 636-640.
14. Gsur A,Zidek T,Schnattinger K,Feik E,Haidinger G,Hollaus P,Mohn-Staudner A,Armbruster C,Madersbacher S,Schatzl G,Trieb K,Vutuc C,Micksche M. 2003. Association of microsomal epoxide hydrolase polymorphisms and lung cancer risk. Br J Cancer 89: 702-706.
15. Hassett C,Aicher L,Sidhu JS,Omiecinski CJ. 1994. Human microsomal epoxide hydrolase: genetic polymorphism and functional expression in vitro of amino acid variants. Hum Mol Genet 3: 421-428.
16. Haycock JW. 2002. Peptide substrates for ERK1/2: structure-function studies of serine 31 in tyrosine hydroxylase. J Neurosci Methods 116: 29-34.
17. Haycock JW,Wakade AR. 1992. Activation and multiple-site phosphorylation of tyrosine hydroxylase in perfused rat adrenal glands. J Neurochem 58: 57-64.
18. Hirsch EC,Hunot S,Damier P,Brugg B,Faucheux BA,Michel PP,Ruberg M,Muriel MP,Mouatt-Prigent A,Agid Y. 1999. Glial cell participation in the degeneration of dopaminergic neurons in Parkinson's disease. Adv Neurol 80: 9-18.
19. Jackson-Lewis V, Przedborski S. 2007. Protocol for the MPTP mouse model of Parkinson's disease. Nat Protoc 2: 141-151.
20. Kohutnicka M,Lewandowska E,Kurkowska-Jastrzebska I,Czlonkowski A,Czlonkowska A. 1998. Microglial and astrocytic involvement in a murine model of Parkinson's disease induced by 1 -methyl-4-phenyl- 1,2,3,6-tetrahydropyridine (MPTP). Immunopharmacology 39: 167-180.
21. Lancaster JM,Brownlee HA,Bell DA,Futreal PA,Marks JR,Berchuck A,Wiseman RW,Taylor JA. 1996. Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinogen 17: 160-162.
22. Langston JW,Ballard P,Tetrud JW,Irwin I. 1983. Chronic Parkinsonism in humans due to a product of mepericline-analog synthesis. Science 219(4587): 979-980.
23. Lew JY, Garcia- Espana A,Lee KY,Carr KD,Goldstein M,Haycock JW,Meller E. 1999. Increased site-specific phosphorylation of tyrosine hydroxylase accompanies stimulation of enzymatic activity induced by cessation of dopamine neuronal activity. Mol Pharmacol 55: 202-209.
24. Liu M,Sun A,Shin EJ,Liu X,Kim SG,Runyons CR,Markesbery W,Kim HC,Bing G. 2006. Expression of microsomal epoxide hydrolase is elevated in Alzheimer's hippocampus and induced by exogenous beta-amyloid and trimethyl-tin. Eur J Neurosci 23: 2027-2034.
25. ?? ack AL.Thiruchelvam M,Manning-Bogr AB,Thiffault C, Langston JW, Cory-Slechta DA, Di Monte DA. 20U. Environmental risk factors and Parkinson's disease: selective degeneration of nigral dopaminergic neurons caused by the herbicide paraquat. Neurbiol Dis 10: 119-127.
26. McCulloch RI,Daubner SC,Fitzpatrick PF. 2001. Effects of substitution at serine 40 of tyrosine hydroxylase on catecholamine binding. Biochemistry 40: 7273-7278.
27. McGlynn KA,Rosvold EA,Lustbader ED,Hu Y,Clapper ML,Zhou T,Wild CP,Xia XL,Baffoe-Bonnie A,Ofori-Adjei D,Chen GC,London WT,Shen FM,Buetow KH. 1995. Susceptibility to hepatocellular carcinoma is associated with genetic variation in the enzymatic detoxification of aflatoxin B1. Proc Natl Acad Sci U S A 92: 2384-2387.
28. Mittal RD,Srivastava DL. 2007. Cytochrome P4501A1 and microsomal epoxide hydrolase gene polymorphisms: gene-environment interaction and risk of prostate cancer. DNA Cell Biol 26: 791-798.
29. Miyata M,Kudo G,Lee YH,Yang TJ,Gelboin HV,Fernandez-Salguero P,Kimura S,Gonzalez FJ. 1999. Targeted disruption of the microsomal epoxide hydrolase gene. Microsomal epoxide hydrolase is required for the carcinogenic activity of 7,12-dimethylbenz[a]anthracene. J Biol Chem 274: 23963-23968.
30. Omiecinski CJ,Aicher L,Holubkov R,Checkoway H. 1993. Human peripheral lymphocytes as indicators of microsomal epoxide hydrolase activity in liver and lung. Pharmacogenetics 3: 150-158.
31. Pekny M,Nilsson M. 2005. Astrocyte activation and reactive gliosis. Glia 50: 427-434.
32. Rozas G,Guerra MJ,Labandeira-Garcia JL. 1997. An automated rotarod method for quantitative drug-free evaluation of overall motor deficits in rat models of parkinsonism. Brain Res Brain Res Protoc 2: 75-84.
33. Salvatore MF,Waymire JC,Haycock JW. 2001. Depolarization-stimulated catecholamine biosynthesis: involvement of protein kinases and tyrosine hydroxylase phosphorylation sites in situ. J Neurochem 79: 349-360.
34. Schmitz C,Hof PR. 2005. Design-based stereology in neuroscience. Neuroscience 130: 813-831.
35. Semchuk KM,Love EJ,Lee RG. 1991. Parkinson's disease and exposure to rural environmental factors: a population based case-control study. Can J Neurol Sci 18: 279-286.
36. Serra PA,Sciola L,Delogu MR,Spano A,Monaco G,Miele E,Rocchitta G,Miele M,Migheli R,Desole MS. 2002. The neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine induces apoptosis in mouse nigrostriatal glia. Relevance to nigral neuronal death and striatal neurochemical changes. J Biol Chem 277: 34451-34461.
37. Shou M,Gonzalez FJ,Gelboin HV. 1996. Stereoselective epoxidation and hydration at the K-region of polycyclic aromatic hydrocarbons cDNA-expressed cytochromes P450 1A1, 1A2, and epoxide hydrolase. Biochemistry 35: 15807-15813.
38. Skoda RC,Demierre A,McBride OW,Gonzalez FJ,Meyer UA. 1988. Human microsomal xenobiotic epoxide hydrolase. Complementary DNA sequence, complementary. DNA-directed expression in COS-1 cells, and chromosomal localization. J Biol Chem 263: 1549-1554.
39. Vijitruth R,Liu M,Choi DY,Nguyen XV,Hunter RL,Bing G. 2006. Cyclooxygenase-2 mediates microglial activation and secondary dopaminergic cell death in the mouse MPTP model of Parkinson's disease. J Neuroinflammation 3: 6.
40. West MJ,Slomianka L,Gundersen HJ. 1991. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231: 482-497.
41. Zhang Y,Porat RM,Alon T,Keshet E,Stone J. 1999. Tissue oxygen levels control astrocyte movement and differentiation in developing retina. Brain Res Dev Brain Res 118: 135-145.
42. Zigmond MJ. 1997. Do compensatory processes underlie the preclinical phase of neurodegenerative disease? Insights from an animal model of parkinsonism. Neurobiol Dis 4: 247-253.